Glargine and cancer: Can we now suggest closure?

Diabetes Care

Volumn 35, Issue 12, 2012, Pages 2426-2428

  Owens, David R ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; INSULIN GLARGINE; PROINSULIN; SOMATOMEDIN C;

BINDING AFFINITY; CANCER RISK; CELL PROLIFERATION; DIABETIC RETINOPATHY; DRUG EFFICACY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALIGNANT NEOPLASTIC DISEASE; MITOGENICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; OSTEOSARCOMA CELL; RISK ASSESSMENT; SINGLE DRUG DOSE; TREATMENT DURATION;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE;

EID: 84869744316     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1968     Document Type: Note

References (28)

1. Bolli GB, Hahn AD, Schmidt R, et al. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Diabetes Care 2012;35:2626-2630
2. Lucidi P, Porcellati F, Rossetti P, et al. Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes. Diabetes Care 2012; 35:2647-2649
3. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367: 319-328
4. Kurtzhals P, Schäffer L, Sørensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49:999-1005 (Pubitemid 30349423)
5. Jorgensen L, Dideriksen L, Drejer K. Carcinogenic effect of the human unsulin analogue B10Asp in female rats. Diabetologia 1992;35(Suppl. 1):A3
6. Drejer K. The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev 1992;8:259-285
7. Dideriksen LH, Jorgensen LN, Drejer K. Carcinogenic effect on female rats after 12 months administration of the insulin analogue B10 Asp. Diabetes 1992;41 (Suppl. 1):143A
8. Stammberger I, Bube A, Durchfeld-Meyer B, Donaubauer H, Troschau G. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 2002;21:171-179 (Pubitemid 34803492)
9. Sandow J. Growth effects of insulin and insulin analogues. Arch Physiol Biochem 2009;115:72-85
10. Sciacca L, Cassarino MF, Genua M, et al. Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia 2010;53:1743-1753
11. Kuerzel GU, Shukla U, Scholtz HE, et al. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin 2003;19:34-40 (Pubitemid 36378318)
12. Agin A, Jeandidier N, Gasser F, Grucker D, Sapin R. Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay. Diabetes Metab 2007;33: 205-212 (Pubitemid 46863409)
13. Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53:1614-1620 (Pubitemid 38697678)
14. Ciaraldi TP, Sasaoka T. Review on the in vitro interaction of insulin glargine with the insulin/insulin-like growth factor system: potential implications for metabolic and mitogenic activities. Horm Metab Res 2011;43:1-10
15. Sommerfeld MR, Müller G, Tschank G, et al. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS ONE 2010;5:e9540
16. Davis MD, Beck RW, Home PD, Sandow J, Ferris FL. Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin. Exp Clin Endocrinol Diabetes 2007; 115:240-243 (Pubitemid 46762251)
17. Rosenstock J, Fonseca V, McGill JB, et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 2009;52: 1971-1973
18. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52:1732-1744
19. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-1777
20. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdò ttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009;52:1745-1754
21. Colhoun HM SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009;52: 1755-1765
22. Pocock SJ, Smeeth L. Insulin glargine and malignancy: an unwarranted alarm. Lancet 2009;374:511-513
23. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009;52:2499-2506
24. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010;60:207-221
25. Porcellati F, Rossetti P, Busciantella NR, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 2007;30:2447-2452 (Pubitemid 47547770)
26. Pierre-Eugene C, Pagesy P, Nguyen TT, et al. Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2. PLos One 2012;7:e41992
27. Blin P, Lassalle R, Dureau-Pournin C, et al. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia 2012;55:644-653
28. Danne T, Johnston P, Xiang G, Cali A, Dain M.-P, Philotheou A. Insulin glargine metabolite M1 is the principal insulin component in plasma of young children with type 1 diabetes: results from the PRESCHOOL study. Diabetologia 2012; 55(Suppl. 1):A946